Stay updated on Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    Site revision: from v3.4.3 to v3.5.0. This appears to be an update to the site version without changes to the study details or information presented on the page.
    Difference
    0.1%
    Check dated 2026-03-19T04:12:17.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Revision: v3.4.3 was added and Revision: v3.4.2 was removed. This reflects a minor platform update without affecting study data or essential content.
    Difference
    0.1%
    Check dated 2026-03-11T20:15:10.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 to the page footer. Removed the lapse-of-funding notice and Revision: v3.4.1 from the footer.
    Difference
    0.4%
    Check dated 2026-02-11T09:17:58.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding and NIH operating status was added, and the page shows Revision: v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T05:20:39.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    Added a 'Show glossary' option, introduced a page revision tag (Revision: v3.4.0), and made minor capitalization/wording changes to labels (e.g., QC criteria wording and No FEAR Act data). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T03:14:52.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    Removed sponsor branding and related links (e.g., Merck Clinical Trials Information and Merck Sharp & Dohme LLC) along with IPD sharing details and drug/MeSH terms from the page. This changes cosmetic/auxiliary content without altering core study information such as study design, treatment arms, outcomes, or eligibility.
    Difference
    19%
    Check dated 2026-01-21T02:48:41.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial page.